Coherus BioSciences (CHRS)

• Market cap: $119M
• 1 day: 3.04%
• 5 days: -5.50%
• 1 month: 27.63%
• 3 months: -23.70%
• 6 months: 37.35%
• Year to date: -26.43%
• 1 year: -47.45%
• 5 years: -93.80%
• 10 years: -95.27%
• Sector: Healthcare
• Industry: Biotechnology

About: Coherus BioSciences Inc is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline which includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer.

Employees: 228

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

4,679% more call options, than puts

Call options by funds: $7.36M | Put options by funds: $154K

13% more capital invested

Capital invested by funds: $79.9M [Q3] → $90.1M (+$10.1M) [Q4]

9% less repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 33

5% less funds holding

Funds holding: 129 [Q3] → 122 (-7) [Q4]

10.13% less ownership

Funds ownership: 66.8% [Q3] → 56.66% (-10.13%) [Q4]

17% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 35

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1.05 2% upside
• Avg. target: $4.03 291% upside
• High target: $7 580% upside

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

HC Wainwright & Co. Douglas Tsao 26% 1-year accuracy 44 / 171 met price target	580% upside $7	Buy Reiterated	29 Apr 2025
UBS Ashwani Verma 25% 1-year accuracy 5 / 20 met price target	2% upside $1.05	Neutral Maintained	24 Apr 2025